Hepatitis Monthly

Published by: Kowsar

Heterozygous Inactivation of the Nuclear Receptor PXR/NR1I2 in a Patient With Anabolic Steroid-Induced Intrahepatic Cholestasis

Roman Liebe 1 , * , Marcin Krawczyk 1 , 2 , Joanna Raszeja-Wyszomirska 2 , Beata Kruk 2 , Rebecca Preis 3 , Jocelyn Trottier 4 , Olivier Barbier 4 , Piotr Milkiewicz 2 , 5 and Frank Lammert 1
Authors Information
1 Department of Medicine II, Saarland University, Homburg, Germany
2 Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland
3 Gemeinschaftspraxis fur Humangenetik, Homburg, Germany
4 CHU-Quebec, Research Center and the Faculty of Pharmacy, Laval University, Quebec, Canada
5 Department of Clinical and Molecular Biochemistry, Pomeranian Medical University, Szczecin, Poland
Article information
  • Hepatitis Monthly: August 01, 2016, 16 (8); e35953
  • Published Online: July 23, 2016
  • Article Type: Case Report
  • Received: January 2, 2016
  • Revised: May 12, 2016
  • Accepted: July 9, 2016
  • DOI: 10.5812/hepatmon.35953

To Cite: Liebe R, Krawczyk M, Raszeja-Wyszomirska J, Kruk B, Preis R, et al. Heterozygous Inactivation of the Nuclear Receptor PXR/NR1I2 in a Patient With Anabolic Steroid-Induced Intrahepatic Cholestasis, Hepat Mon. 2016 ; 16(8):e35953. doi: 10.5812/hepatmon.35953.

Abstract
Copyright © 2016, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Introduction
2. Case Presentation
3. Discussion
Footnotes
References
  • 1. Rahnema CD, Crosnoe LE, Kim ED. Designer steroids - over-the-counter supplements and their androgenic component: review of an increasing problem. Andrology. 2015; 3(2): 150-5[DOI][PubMed]
  • 2. Bolding G, Sherr L, Elford J. Use of anabolic steroids and associated health risks among gay men attending London gyms. Addiction. 2002; 97(2): 195-203[PubMed]
  • 3. Gerber PA, Kukova G, Meller S, Neumann NJ, Homey B. The dire consequences of doping. Lancet. 2008; 372(9639): 656[DOI][PubMed]
  • 4. Robles-Diaz M, Gonzalez-Jimenez A, Medina-Caliz I, Stephens C, Garcia-Cortes M, Garcia-Munoz B, et al. Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids. Aliment Pharmacol Ther. 2015; 41(1): 116-25[DOI][PubMed]
  • 5. Trottier J, Caron P, Straka RJ, Barbier O. Profile of serum bile acids in noncholestatic volunteers: gender-related differences in response to fenofibrate. Clin Pharmacol Ther. 2011; 90(2): 279-86[DOI][PubMed]
  • 6. Trottier J, Bialek A, Caron P, Straka RJ, Milkiewicz P, Barbier O. Profiling circulating and urinary bile acids in patients with biliary obstruction before and after biliary stenting. PLoS One. 2011; 6(7)[DOI][PubMed]
  • 7. Trottier J, Perreault M, Rudkowska I, Levy C, Dallaire-Theroux A, Verreault M, et al. Profiling serum bile acid glucuronides in humans: gender divergences, genetic determinants, and response to fenofibrate. Clin Pharmacol Ther. 2013; 94(4): 533-43[DOI][PubMed]
  • 8. Brennan BP, Kanayama G, Pope HJ. Performance-enhancing drugs on the web: a growing public-health issue. Am J Addict. 2013; 22(2): 158-61[DOI][PubMed]
  • 9. El Sherrif Y, Potts JR, Howard MR, Barnardo A, Cairns S, Knisely AS, et al. Hepatotoxicity from anabolic androgenic steroids marketed as dietary supplements: contribution from ATP8B1/ABCB11 mutations? Liver Int. 2013; 33(8): 1266-70[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments